Research programme: monoclonal antibodies - ElsaLys Biotech

Drug Profile

Research programme: monoclonal antibodies - ElsaLys Biotech

Alternative Names: anti-CD115 monoclonal antibodies - Transgene; ELB-041; TG 3003

Latest Information Update: 20 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transgene
  • Developer ElsaLys Biotech; Transgene
  • Class Monoclonal antibodies
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants; Macrophage colony-stimulating factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Solid tumours

Most Recent Events

  • 15 Dec 2016 ElsaLys Biotech acquires development and marketing rights for ELB 041
  • 21 Apr 2015 Pharmacodynamics data from preclinical trials in presented at the 106th Annual Meeting of the American Association for Cancer Research (AACR-2015)
  • 19 Mar 2015 Preclinical development is underway in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top